News archive
Showing 700 results
April 2012
-
Media Release
Higher dose of Novartis drug Exelon® Patch showed statistically significantly less decline in function in Alzheimer’s vs. lower dose
-
Media Release
New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
Results from open label phase III extension and 7-year phase II extension studies show sustained low disease activity on clinical and MRI measures in patients continuing on Gilenya (fingolimod)… -
Media Release
New extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
-
Media Release
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
Prescribing information (PI) includes new patient selection parameters based on certain cardiovascular considerations to aid in identifying patients for GilenyaUpdated Gilenya prescribing information… -
Media Release
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
-
Media Release
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
Now available in US pharmacies, Hecoria (tacrolimus) capsules are approved for the prevention of organ rejection in certain kidney and liver transplant patientsHecoria, a branded generic, complements… -
Media Release
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
March 2012
-
Media Release
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
- Arcapta Neohaler is the only once-daily, 24-hour long-acting beta2-agonist approved for maintenance treatment of airflow obstruction in COPD patients- Arcapta Neohaler showed significant… -
Media Release
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
January 2012
-
Media Release
Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
- Company to resolve wage and hour claims with one-time payment of up to 99 million dollars for eligible class members- Novartis Pharmaceuticals Corporation remains committed to compensate all… -
Media Release
Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims